Introduction
Stroke is a leading cause of mortality and subsequent serious long-term disability among survivors. 1, 2 In the elderly, ischemic stroke, which can be due to a sudden interruption in the blood supply to the brain, accounts for more than 80% of all stroke cases. 3, 4 At present, the absence of a widely available and sensitive diagnostic test for acute cerebral ischemia remains a significant limitation in the diagnosis and management of stroke. Except for clinical decisions, radio diagnoses are usually used for the diagnosis of ischemic stroke. Early ischemic changes may be subtle or absent on CT scans. It is accepted that several technologies based on MRI have shown promise for the early diagnosis of ischemic stroke. 5 However, as a practical issue, most hospitals do not have these specialized MRI services available in an acute setting. Another approach to the diagnosis of acute stroke is to evaluate blood-borne biochemical markers of brain tissue injury. Neurobiochemical markers of brain damage gained particular attention in patients with vascular and traumatic brain during the last decade. Due to commercial availability, protein S100β and neuron-specific enolase (NSE) were most often studied. In patients with ischemic stroke, a number of studies showed a significant association between clinical deficit, infarction volume, functional disability, and the release of protein S100β, which is a glial-derived protein, indicating that the serum levels may add information to the stroke course and the short-term outcome. [6] [7] [8] [9] NSE is a dimeric isoenzyme of the glycolytic enzyme enolase, and derives from neuronal cytoplasm and neuroendocrine cells. Several studies have demonstrated significantly lower NSE concentrations in controls than in patients with acute ischemic stroke. 10 Thus, an ideal biomarker-based detection strategy should be capable of the simultaneous and ultrasensitive detection of a limited suite of such biomarkers in complex biological samples. However, the simultaneous detection of these two biomarkers in blood is often challenging, since the NSE level is around 2 orders of magnitude higher than the S100β content.
The multiplex detection of markers has facilitated clinical diagnosis, drug discovery, and environmental testing. Compared with traditional single-analyte tests, accurate simultaneous multianalyte immunoassays of combinations of biomarker may shorten the analytical time, offer a higher sample throughout, a lower sample volume and the cost per assay. 11, 12 So far, two dominant modes have been utilized for multiplex immunoassay. 13 One is the spatial resolution of different immunoassay areas using a universal label for fluorescent, 14 chemiluminescent (CL), 15, 16 spectrophotometric, 17 electrochemical 18, 19 and surface-enhanced Raman spectroscopy (SERS). 20 These methods commonly call for costly array detectors, such as a charge-coupled device (CCD) camera or multichannel electrochemical workstation. As for the electrochemical sensor array, it is susceptible to the cross-talk potentially occurring due to the diffusion of an electroactive product generated at one electrode to a neighboring electrode. The other is the multilabel mode applying different labels (one per analyte) for tagging the antibodies or antigens corresponding to the analytes. † To whom correspondence should be addressed. Herein we have demonstrated a novel protocol to integrating two immunoassay procedures for performing a sequential dual-protein determination, based on a chemiluminescence (CL) substrate-resolved technology. We evaluated our method for the sequential determination of S100β and neuron-specific enolase (NSE) by using alkaline phosphatase (ALP) and horseradish peroxidase (HRP) as two different labels. Especially sharply different and suitable linear ranges and detection limits were successfully obtained for these two markers. Briefly, a "sandwich-type" detection strategy is employed in our design, where capture antibodies against S100β and NSE were coupled to magnetic beads. The quantification of NSE was obtained by further reacting with ALP modified antibodies and measurements by catalyzed chemiluminescence while the determination of S100β was accomplished with HRP-labeled anti-rabbit IgG. A simple CL setup was employed to perform our novel multiplexed protein assays in a single experiment. No obvious cross-reaction was observed. S100β and NSE were found to be suitably assayed in the ranges of 0.02 -1 and 1 -20 ng/mL, and the limits of detection were 0.005 and 0.2 ng/mL for S100β and NSE, respectively. It is straightforward to adapt this strategy to detect a spectrum of other biomarkers, which can provide important information about the early-stage diagnosis of diseases. This strategy is performed with different labels, including enzymes, [21] [22] [23] [24] metal ions, 25, 26 fluorescent labels 27, 28 and nanocrystals. 29 The simultaneous detection of the analytes requires a compromise under the optimal assay conditions, and needs to overcome the signal overlapping of different labels.
Chemiluminescence (CL) detection has been widely used in sensitive immunoassay due to its wide calibration range, no need for complicated instruments, and suitability for miniaturization. The horseradish peroxidase (HRP)-based CL reaction is based on the catalyzed oxidation of luminol by hydrogen peroxide, in which the aminophthalate ion emits light as it decays to the ground state. Alkaline phosphatase (ALP) is another enzyme that reacts with adamantane to emit a strong CL. Both of these CL techniques provide a fast and safe detection method with high sensitivity, having potential for use in such applications as Western or dot/slot/spot blotting. In addition, magnetic beads (MB) as special biomolecule immobilizing carriers offer a promising alternative to conventional methodology. MB has been used in immunoassays, enzyme, DNA, and protein immobilization, DNA purification, and magnetically controlled transport of anticancer drugs. 30 A fast homogeneous immunoreaction as well as a simple heterogeneous separation process was carried out in the light of some certain characteristics of water-dispersed MB, and thus lower nonspecific affinity and higher sensitivity were accomplished. For example, Peng et al. 31 employed MB for the aptamer-barcode based immunoassay of human IgE by taking advantage of a magnetic separation/mixing process. Csordas et al. 32 coupled microfluidic magnetic sample preparation with highly specific aptamer-based molecular recognition and quantitative PCR for the detection of a platelet-derived growth factor. In this article, to demonstrate our original idea, we illustrate an attempt to introduce streptavidin modified MB, which enables assays to be performed homogeneously, and also provides means to concentrate the signal-generating samples, and designed a MB-based CL substrate-resolved duplex immunoassay system for the sequential detection of two ischemic stroke markers, S100β and NSE, which have great medical values in the early screening and clinical diagnosis of stroke. The obtained results are in acceptable agreement with those from the parallel single-analyte test. This strategy possesses attractive characteristics, such as low cost, simple manipulation, and easy separation steps.
Experimental

Reagents and chemicals
All chemicals were of analytical reagent grade and were used as received. Ultrapure water obtained from a Millipore water purification system was used in all runs. The streptavidinmodified MB (SA-MB) in an aqueous suspension with the mean diameter of 1.5 μm and concentration of 5 mg/mL was obtained from Polysciences (Warrington, PA). Bovine serum albumin (BSA) was purchased from Shanghai Aizite Life Science & Technology Co. Ltd., China. Detection and capture monoclonal antibody pairs specific to NSE were purchased from Shanghai Linc-Bio Science Co., China. Monoclonal anti-S100β antibody was purchased from Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal anti-S100 antibody was purchased from DAKO (2.3 mg/mL). Natural purified S100β antigen (ββ homodimer, human) and NSE antigen were purchased from Hytest Ltd. and Sigma, respectively.
Fluorescein isothiocyanate (FITC), monoclonal anti-FITC alkaline phosphatase conjugate (anti-FITC ALP, 2 mg/mL) and anti-rabbit IgG-HRP (0.9 mg/mL) were bought from Sigma.
EZ-Link sulfo-NHS-biotin was bought from Pierce. ALP CL substrate (AMPPD) and HRP CL substrates (Luminol Reagent and Peroxide Solution) were purchased from Millipore. Other chemical reagents were sourced from Sinopharm Chemical Reagent Co. Ltd.
Coupling buffer for the first step of sandwich immunoassay was 0.01 M pH 7.4 phosphate buffered saline (PBS); 0.01 M Tris buffer (pH 7.4, 2 mM Ca 2+ included) was employed for the second step of immunoreactions (antigen and detection antibody), but PBS was chosen again for the last reaction of the detection antibody and the respective enzyme. Blocking buffer was PBS containing 10% BSA. To minimize unspecific adsorption, 0.05% Tween 20 was spiked into PBS as a wash buffer (PBST).
Apparatus
UV absorbance was determined by a HITACHI U-2900 spectrophotometer. The CL intensity was determined with a PC-controlled Fluoroskan Ascent FL (Thermo Electron Corp.).
Preparation of anti-S100β immobilized MBs and anti-NSE immobilized MBs
All capture antibodies were biotinylated before binding to the surface of MBs. Briefly, the capture antibodies were biotinylated by using sulfo-NHS-biotin (20 molar excess) to allow their immobilization on the surface. The antibody, in PBS, was mixed with the EZ-Link sulfo-NHS-biotin, and incubated at 4 C for 2 h. Free biotins were removed by dialyzing with PBS. The coupling of antibodies to MB was performed via the streptavidin-biotin reaction, the most prevalent noncovalent biological interaction ever known. SA-MB without blocking with PBS containing 10% BSA was easy to absorb to the tubes and difficult to be separated freely. Thus, in a typical experiment, 10 μg of the streptavidin-modified MBs were transferred to tubes, washed with PBST and resuspended in 200 μL blocking buffer. After being incubated for 30 min at 37 C, the mixture was positioned into a magnetic separator to remove the blocking buffer. A capture antibody (5 μg/mL of anti-S100β and 1 μg/mL of anti-NSE capture antibody diluted in PBS) was added, and the resultant mixture was incubated for 30 min at 37 C with gentle mixing. The bead-antibody conjugates were washed 3 times with 150 μL of PBST and dispersed in 200 μL of PBS containing 2% BSA before use.
FITC labeling of NSE detection antibody
NSE detection antibody (150 μL) was concentrated in a 90-μL sodium carbonate solution (pH 9.2, 0.1 M) using a 50000 NMWL MICROCON Centrifugal Filter device, and then 10 μL of FITC in 0.1 M sodium carbonate solution (1 mg/mL) was added. The reaction mixture was incubated at room temperature for 1 h with continuous stirring. The NSE-FITC conjugate obtained was dialyzed overnight against a sodium carbonate solution, and then against pH 7.0 phosphate buffer saline (PBS) for another 12 h. The resultant FITC-modified NSE detection antibody was concentrated in 150 μL PBS, and then stored at -20 C before use. The final concentration of FITC modified NSE detection antibody was determined by UV as being 1.00 mg/mL.
Immunoassay protocol
The assay process for NSE and S100β is illustrated in Scheme 1, and was conducted as follows: 10 μg NSE bead-antibody conjugates and 10 μg S100β bead-antibody conjugates were mixed and received calibrators or specimens diluted with 2% BSA in a total of 100 μL. The mixture was incubated with continuous shaking at 37 C for 1 h. The immunocomplexes were accumulated and washed under an external magnetic field. Then 100 μL of the detection antibody for NSE (1 μg/mL) and S100β (1:2000 dilution, 1.15 μg/mL) was added, and shaking continued for a further 1 h. The MB conjugates were washed twice and 100 μL each of anti-FITC ALP (1:10000, 0.2 μg/mL), goat-anti-rabbit IgG HRP (1:2000, 0.45 μg/mL) were added and reacted for another 1 h at 37 C. After washing three times with 150 μL PBST, the MB was divided into two parts. One part was then directly detected with 100 μL HRP CL substrate for the determination of S100β, the other part was detected with 50 μL ALP CL substrate for obtaining the NSE concentration.
Results and Discussion
MB is water-dispersed as capture antibody immobilizing carriers. Consequently, the sandwich immunoreactions can be performed under homogeneous conditions and the MB can be separated from the unbound molecules by magnetic force. In addition, no noticeable cross-talk of the CL signals between ALP and HRP was found. The CL signal from each label could thus be determined sequentially in one tube, and in the measurement order of ALP and HRP. The signal of ALP was observed to decrease considerably when measured after HRP because of exposure to the DMSO solution of the HRP substrate; also, the washing step must be introduced after the first run of measuring HRP to remove the substrate and possible signal carryover. However, for simplicity, we directly divided the resultant sample equally into two parts after the last step of washing; each part was used for a direct measurement of one specific label after adding the corresponding substrate. Note that this simple and quick detection procedure decreased the sensitivity by 2 fold, but avoided any in-between washing.
Optimization of the assay and generation of standard curves
The duplex assay was optimized systematically for the amounts of the two capture antibodies, the two magnetic bead-antibody conjugates, the two corresponding detection antibodies and anti-rabbit IgG-HRP and anti-FITC ALP. A series of experiments were conducted with varying amounts of every reagent per group. As the amount of each capture antibody increased, the CL signal-to-noise ratio (CL ratio) initially increased, and reached a maximum (Fig. 1) , which possibly occurred due to gradual saturation of the binding sites on the MB surface. After that, the CL background was increased, and thus the CL ratio decreased quickly, possibly due to nonspecific adsorption from an excess of capture antibodies. Hence, subsequent work employed 5 μg/mL of S100β and 1 μg/mL of NSE as the optimum capture antibodies.
The amount of bead-antibody conjugates was optimized so as to offer a higher CL ratio. As described in Fig. 2 , better performance was achieved with 10 μg S100β bead-antibody conjugates, and 5 μg NSE bead-antibody conjugates, and the calculated antibody density on the surface of MBs was 0.05 μg S100β capture antibody per μg MB, 0.02 μg NSE capture antibody per μg MB, respectively. However, it is not easy to keep a good reproducibility by using 5 μg NSE bead-antibody conjugates; thus, both 10 μg S100β bead-antibody conjugates and 10 μg NSE bead-antibody conjugates were employed in following experiments.
Similarly, the amount or the dilution of the detection antibody (as shown in Fig. 3, (A) for the dilution of S100β polyclonal antibody, (B) for the NSE-detection antibody) was also optimized. Thus, 1:2000 diluted S100β polyclonal antibody detection antibodies and 1 μg/mL FITC-modified NSE detection antibody were chosen in subsequent work.
In addition, the dilutions of anti-FITC-ALP and anti-rabbit IgG-HRP were optimized to achieve a higher S/N. It was suggested that the ideal dilution is 1:2000 for anti-rabbit IgG-HRP, 1:10000 for anti-FITC-ALP (Fig. 4) .
Under the above-optimized conditions, the CL intensity for both NSE and S100β increased with increasing concentration of the analytes. A linear relationship was obtained between the CL intensity and the amount of S100β in the concentration range of 0.02 -1.00 ng/mL (y = 259306x + 1928, R 2 = 0.9998); the detection limit was estimated to be 0.005 ng/mL, while the dynamic range was extended to between 1 and 20.00 ng/mL for NSE (y = 12055x + 7625, R 2 = 0.9968); the detection limit was 0.20 ng/mL. The detection limit was obtained from three times the standard deviation, corresponding to the blank sample detection, respectively, which is competitive with, or better than, other immunoassays. 11, 33, 34 
Evaluation of cross reactivity
The results of combined single assays are reliable only if cross-reactivity between the reagents is undetectable. To investigate the cross-reactivity between NSE and anti-S100β or S100β and anti-NSE, 2 ng/mL NSE or 0.2 ng/mL S100β was spiked with variable amounts of S100β or NSE, and tested in the immunoassay technique, respectively.
The following sandwich reaction and the detection procedure were carried out as described in the Experimental section. The CL intensity obtained for every concentration of NSE or S100β is shown in Fig. 5 . The presence of variable amounts of S100β did not change the CL signal of 2 ng/mL NSE. Similarly, the presence of variable amounts of NSE showed no obvious influence on the CL signal of 0.2 ng/mL S100β. Hence, there was no cross-talk between the two pairs of immunoreactions.
Validation of precision and recovery
The low intra-assay variation allowed for the analysis of single samples, which may save valuable sample volume. The reproducibility of the CL substrate-resolved multianalyte immunoassay was assessed by intra-and inter-assay CVs. The intra-assay precisions (n = 4) and the inter-assay precision over 3 days were found to be less than 10% for both S100β and NSE. The recoveries of S100β (0.1, 0.2 and 0.5 ng/mL) in the presence of 10 ng of NSE were 83.7 -113.8%, while the recoveries of NSE (1, 2 and 10 ng) in the presence of 1 ng of S100β were 87.5 -113%. Thus, this technology can be used for the simultaneous determination of two proteins in a single sample.
Conclusions
A novel duplex CL immunoassay platform for the determination of two proteins has been demonstrated. MB is water-dispersed, and thus two immunoreactions can be carried out in a single vessel, and the separation of MB conjugates can be easily achieved by magnetic force. In addition, the CL signal from ALP and HRP can be determined sequentially in the measurement order of ALP and HRP without any obvious Fig. 5 Cross reactivity of NSE to anti-S100β in the presence of variable amounts of S100β (A) and S100β to anti-NSE in the presence of variable amounts of NSE (B). The detection procedure was carried out as described in the Experimental section. Experimental conditions: 10 μg SA-MB; (A) 5 μg/mL S100β capture antibody, 0.2 ng/mL S100β and 1:2000 S100β polyclonal antibody; (B) 1 μg/mL NSE capture antibody, 5 ng/mL NSE and 1 μg/mL NSE detection antibody. The detection procedure was carried out as described in the Experimental section.
cross-reaction. This method has the following three advantages over previous methods: 1) S100β and NSE are successfully determined with sharply different but suitable linear ranges, and detection limits in a single experiment with a single sample, thus consuming less time and sample with good accuracy and precision; 2) this assay technique is an attractive alternative due to such features as low cost, easy automation and simple manipulation; 3) this assay technique is a general method. Upon modification, the approach presented herein can be easily extended to detect other types of disease markers, and also other types of labels, such as nanoparticles. Therefore, this simple and homogeneous technique is expected to be a candidate for the detection of proteins and other ligands of interest in such areas as care diagnostics and personalized medicine at the point of care.
